Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, recommends new novel topical therapies over topical steroids for patients with atopic dermatitis (AD).
Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, recommends that patients with atopic dermatitis (AD) ask their dermatologists about new topical therapies instead of using topical steroids.
Transcript
What advice do you have for patients with atopic dermatitis who are seeking new treatment options or struggling to manage their symptoms?
That's a really, really important question because, unfortunately, what I see among a lot of dermatologists, and what I hear when I see eczema patients coming into my office for clinical trials, is that many of them have only been offered topical steroids for years and years and years. I referred to that earlier when I said a "serial topical prescriber" over and over and over again, so the patients think that there's nothing else.
My advice to patients is to know that there are a number of great treatments available out there—not only systemic treatments as I discussed (such as) oral JAK inhibitors and biologics, but a number of new novel topical therapies. Not just topical ruxolitinib, but we're going to see topical tapinarof and topical roflumilast approved for atopic dermatitis with nonsteroidal topical options that work terrifically.
My advice to patients is push your dermatologist. Push them away from topical steroids, which I think is actually a horrible treatment for long-term management of AD. I think it's fine for short-term knockout of the disease, but for long-term management of a chronic disease, I think topical steroids are a poor choice, and yet you'II see that over and over again in practice, and patients tell you over and over again.
So, get out of the topical steroid rut. Ask your doctors about the novel new treatments, many of which are going to be better options than that topical steroid route that patients have done for so many years.
This transcript has been lightly edited for clarity.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More